Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma

ACS Chemical Biology

Volumn 9, Issue 5, 2014, Pages 1086-1091

  Wu, Hong ^a,b   Wang, Wenchao ^a   Liu, Feiyang ^a,b   Weisberg, Ellen L ^c   Tian, Bei ^d   Chen, Yongfei ^a   Li, Binhua ^a   Wang, Aoli ^a   Wang, Beilei ^a   Zhao, Zheng ^a   McMillin, Douglas W ^c   Hu, Chen ^a   Li, Hong ^a   Wang, Jinhua ^e   Liang, Yanke ^e   Buhrlage, Sara J ^e   Liang, Junting ^f   Liu, Jing ^a   Yang, Guang ^c   Brown, Jennifer R ^c   Treon, Steven P ^c   Mitsiades, Constantine S ^c   Griffin, James D ^c   Liu, Qingsong ^a,b   Gray, Nathanael S ^e   more..

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HEFEI INSTITUTES OF PHYSICAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVL 292; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CGI 1746; IBRUTINIB; QL 47; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; B CELL LYMPHOMA; CANCER SURVIVAL; CELL PROLIFERATION; DRUG DESIGN; DRUG POTENCY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IC 50; MICHAEL ADDITION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; LYMPHOMA, B-CELL; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG DISCOVERY; HUMANS; LYMPHOMA, B-CELL; MOLECULAR DOCKING SIMULATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84900844060     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4008524     Document Type: Article

References (33)

1. Schmidt, U., Boucheron, N., Unger, B., and Ellmeier, W. (2004) The role of Tec family kinases in myeloid cells Int. Arch. Allergy Immunol. 134, 65-78
2. Berg, L. J., Finkelstein, L. D., Lucas, J. A., and Schwartzberg, P. L. (2005) Tec family kinases in T lymphocyte development and function Annu. Rev. Immunol. 23, 549-600
3. Kersseboom, R., Ta, V. B., Zijlstra, A. J., Middendorp, S., Jumaa, H., van Loo, P. F., and Hendriks, R. W. (2006) Brutons tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement J. Immunol. 176, 4543-4552
4. Uckun, F. M., Tibbles, H. E., and Vassilev, A. O. (2007) Brutons tyrosine kinase as a new therapeutic target Anticancer Agents Med. Chem. 7, 624-632
5. Smith, C. I., Baskin, B., Humire-Greiff, P., Zhou, J. N., Olsson, P. G., Maniar, H. S., Kjellen, P., Lambris, J. D., Christensson, B., and Hammarstrom, L. 1994, Expression of Brutons agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells J. Immunol. 152, 557-565
6. Tsukada, S., Rawlings, D. J., and Witte, O. N. (1994) Role of Brutons tyrosine kinase in immunodeficiency Curr. Opin. Immunol. 6, 623-630
7. Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., Benoit, S. E., Miyashiro, J. S., Wood, N., Mohan, S., Peeva, E., Ramaiah, S. K., Messing, D., Homer, B. L., Dunussi-Joannopoulos, K., Nickerson-Nutter, C. L., Schnute, M. E., and Douhan, J., 3rd (2013) Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis J. Immunol. 191, 4540-4550
8. Mohamed, A. J., Yu, L., Backesjo, C. M., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglof, A., Vihinen, M., Nore, B. F., and Smith, C. I. (2009) Brutons tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol. Rev. 228, 58-73
9. Park, H., Wahl, M. I., Afar, D. E., Turck, C. W., Rawlings, D. J., Tam, C., Scharenberg, A. M., Kinet, J. P., and Witte, O. N. (1996) Regulation of Btk function by a major autophosphorylation site within the SH3 domain Immunity 4, 515-525
10. Mahajan, S., Vassilev, A., Sun, N., Ozer, Z., Mao, C., and Uckun, F. M. (2001) Transcription factor STAT5A is a substrate of Brutons tyrosine kinase in B cells J. Biol. Chem. 276, 31216-31228
11. Glassford, J., Soeiro, I., Skarell, S. M., Banerji, L., Holman, M., Klaus, G. G., Kadowaki, T., Koyasu, S., and Lam, E. W. (2003) BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells Oncogene 22, 2248-2259
12. Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R., and Wortis, H. H. (2000) Brutons tyrosine kinase links the B cell receptor to nuclear factor kappaB activation J. Exp. Med. 191, 1735-1744
13. Petro, J. B. and Khan, W. N. (2001) Phospholipase C-gamma 2 couples Brutons tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes J. Biol. Chem. 276, 1715-1719
14. Hashimoto, S., Iwamatsu, A., Ishiai, M., Okawa, K., Yamadori, T., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T., and Tsukada, S. (1999) Identification of the SH2 domain binding protein of Brutons tyrosine kinase as BLNK-functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling Blood 94, 2357-2364
15. de Weers, M., Verschuren, M. C., Kraakman, M. E., Mensink, R. G., Schuurman, R. K., van Dongen, J. J., and Hendriks, R. W. (1993) The Brutons tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages Eur. J. Immunol. 23, 3109-3114
16. Rodriguez, A., Martinez, N., Camacho, F. I., Ruiz-Ballesteros, E., Algara, P., Garcia, J. F., Menarguez, J., Alvaro, T., Fresno, M. F., Solano, F., Mollejo, M., Martin, C., and Piris, M. A. (2004) Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement Clin. Cancer Res. 10, 6796-6806
17. Ortolano, S., Hwang, I. Y., Han, S. B., and Kehrl, J. H. (2006) Roles for phosphoinositide 3-kinases, Brutons tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing Eur. J. Immunol. 36, 1285-1295
18. Uckun, F., Dibirdik, I., Sarkissian, A., and Qazi, S. (2011) In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Brutons tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors Arzneimittelforschung 61, 252-259
19. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H. M., and Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis Leuk. Res. 37, 1271-1277
20. Liu, Y., Dong, Y., Jiang, Q. L., Zhang, B., and Hu, A. M. (2014) Brutons tyrosine kinase: potential target in human multiple myeloma Leuk. Lymphoma 55, 177-181
21. DCruz, O. J. and Uckun, F. M. (2013) Novel Brutons tyrosine kinase inhibitors currently in development OncoTargets Ther. 6, 161-176
22. Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., Johnson, A. J., Sukbuntherng, J., Chang, B. Y., Clow, F., Hedrick, E., Buggy, J. J., James, D. F., and OBrien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N. Engl. J. Med. 369, 32-42
23. Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., and Blum, K. A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N. Engl. J. Med. 369, 507-516
24. Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A., Darrow, J., Davies, D. R., DeForge, L. E., Diehl, L., Ferrando, R., Gallion, S. L., Giannetti, A. M., Gribling, P., Hurez, V., Hymowitz, S. G., Jones, R., Kropf, J. E., Lee, W. P., Maciejewski, P. M., Mitchell, S. A., Rong, H., Staker, B. L., Whitney, J. A., Yeh, S., Young, W. B., Yu, C., Zhang, J., Reif, K., and Currie, K. S. (2011) Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis Nat. Chem. Biol. 7, 41-50
25. Pan, Z., Scheerens, H., Li, S. J., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C., Grothaus, P. G., Jeffery, D. A., Spoerke, J. M., Honigberg, L. A., Young, P. R., Dalrymple, S. A., and Palmer, J. T. (2007) Discovery of selective irreversible inhibitors for Brutons tyrosine kinase ChemMedChem 2, 58-61
26. Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., Zhu, Z., Nacht, M., Freed, M. I., Petter, R. C., Dubrovskiy, A., Singh, J., and Westlin, W. F. (2013) Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans J. Pharmacol. Exp. Ther. 346, 219-228
27. Liu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., and Gray, N. S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9- (quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer J. Med. Chem. 53, 7146-7155
28. Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., and Gray, N. S. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1- (3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer J. Med. Chem. 54, 1473-1480
29. Liu, F., Zhang, X., Weisberg, E., Chen, S., Hur, W., Wu, H., Zhao, Z., Wang, W., Mao, M., Cai, C., Simon, N. I., Sanda, T., Wang, J., Look, A. T., Griffin, J. D., Balk, S. P., Liu, Q., and Gray, N. S. (2013) Discovery of a selective irreversible BMX inhibitor for prostate cancer ACS Chem. Biol. 8, 1423-1428
30. Carlson, C. B., Mashock, M. J., and Bi, K. (2010) BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds J. Biomol. Screening 15, 327-334
31. Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., and Buggy, J. J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 107, 13075-13080
32. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., and Gray, N. S. (2013) Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20, 146-159
33. Polier, S., Samant, R. S., Clarke, P. A., Workman, P., Prodromou, C., and Pearl, L. H. (2013) ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system Nat. Chem. Biol. 9, 307-312